Poly Medicure Ltd
NSE:POLYMED
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 838.3
2 968.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Poly Medicure Ltd
Poly Medicure Ltd., an Indian manufacturer of medical devices, is a compelling narrative of innovation driving tangible impact in healthcare. It embarked on its journey in the late 1990s, seizing on the escalating demand for high-quality medical consumables. The company carved its niche by producing a wide array of disposable medical devices like catheters, infusion therapy systems, and wound closure products, essential in medical facilities worldwide. By establishing a robust manufacturing infrastructure and leveraging economies of scale, Poly Medicure ensures competitive pricing while adhering to global quality standards. A dedication to research and development undergirds their operation, constantly pushing the envelope of modern medical technology.
Revenue streams flow primarily from the sale of these innovative products to hospitals, healthcare institutions, and distributors across more than 100 countries. The company's strategic positioning in the industry is further reinforced by its commitment to sustainability and stringent adherence to regulatory compliance, which helps in sustaining long-term contracts and partnerships. The expansion of its product range and the adoption of automated manufacturing processes don't just meet but often forecast sector demands. By keeping its pulse on global health trends, Poly Medicure ensures not only stable growth in its financial graphs but also cements its authority as a cornerstone entity in the medical supplies marketplace.
Poly Medicure Ltd., an Indian manufacturer of medical devices, is a compelling narrative of innovation driving tangible impact in healthcare. It embarked on its journey in the late 1990s, seizing on the escalating demand for high-quality medical consumables. The company carved its niche by producing a wide array of disposable medical devices like catheters, infusion therapy systems, and wound closure products, essential in medical facilities worldwide. By establishing a robust manufacturing infrastructure and leveraging economies of scale, Poly Medicure ensures competitive pricing while adhering to global quality standards. A dedication to research and development undergirds their operation, constantly pushing the envelope of modern medical technology.
Revenue streams flow primarily from the sale of these innovative products to hospitals, healthcare institutions, and distributors across more than 100 countries. The company's strategic positioning in the industry is further reinforced by its commitment to sustainability and stringent adherence to regulatory compliance, which helps in sustaining long-term contracts and partnerships. The expansion of its product range and the adoption of automated manufacturing processes don't just meet but often forecast sector demands. By keeping its pulse on global health trends, Poly Medicure ensures not only stable growth in its financial graphs but also cements its authority as a cornerstone entity in the medical supplies marketplace.
Revenue Growth: Q2 revenue reached INR 444 crores, up 5.7% YoY and 10.1% QoQ; H1 revenue was INR 847 crores, up 5.3% YoY.
Margin Performance: Gross margin improved to 69.4% in Q2 (up 900 bps YoY); EBITDA margin remained strong at 26.8%, near the top end of the 25–27% guidance.
Acquisitions: Closed acquisitions of Italy-based Citieffe Group and Netherlands-based PendraCare, expected to add about INR 280 crores to annual revenue.
Guidance Update: FY'26 revenue growth guided at 15–16% (down from earlier 20%); domestic growth expected at 28–30%, international at ~10%. H2 revenue guidance between INR 1,080–1,090 crores.
CapEx Plans: CapEx of INR 150 crores spent in H1; INR 250 crores planned for FY'26; similar level expected in FY'27.
Product Pipeline: 20 new products pending CE mark for Europe in 2026; strong focus on expanding in cardiology and critical care.
Cash Position: Ended Q2 with INR 1,109 crores liquidity; post-acquisitions, net cash stands at around INR 800 crores.